| 3.55 -0.09 (-2.47%) | 01-21 10:04 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.29 |
1-year : | 5.01 |
| Resists | First : | 3.67 |
Second : | 4.29 |
| Pivot price | 3.16 |
|||
| Supports | First : | 2.73 |
Second : | 2.16 |
| MAs | MA(5) : | 3.24 |
MA(20) : | 3.01 |
| MA(100) : | 3.1 |
MA(250) : | 3.34 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 75.8 |
D(3) : | 69.1 |
| RSI | RSI(14): 67.5 |
|||
| 52-week | High : | 6.46 | Low : | 2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ HSCS ] has closed above the upper band by 23.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 10.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.68 - 3.7 | 3.7 - 3.71 |
| Low: | 3.04 - 3.06 | 3.06 - 3.08 |
| Close: | 3.61 - 3.64 | 3.64 - 3.67 |
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Fri, 16 Jan 2026
HeartSciences Signs Note Purchase Agreement With Streeterville Capital - TradingView — Track All Markets
Mon, 22 Dec 2025
Ascendiant Capital Maintains HeartSciences (HSCS) Buy Recommendation - Nasdaq
Mon, 22 Dec 2025
HeartSciences (HSCS) Receives Updated Analyst Rating and Price T - GuruFocus
Mon, 15 Dec 2025
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device - GlobeNewswire
Mon, 15 Dec 2025
HeartSciences (Nasdaq: HSCS) separates device, AI-ECG FDA paths - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 3.06e+006 (%) |
| Held by Institutions | 5.1 (%) |
| Shares Short | 37 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.21e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -85 % |
| Return on Assets (ttm) | 713.2 % |
| Return on Equity (ttm) | -74.8 % |
| Qtrly Rev. Growth | 8670 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -86.78 |
| EBITDA (p.s.) | 1976.37 |
| Qtrly Earnings Growth | -6.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 6.79 |
| Dividend | 0 |
| Forward Dividend | 75970 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|